Menu
Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 7
Use of tazarotene foam for the treatment of acne vulgaris
Authors Gregoriou S, Kritsotaki E, Katoulis A, Rigopoulos D
Received 3 January 2014
Accepted for publication 5 March 2014
Published 27 May 2014 Volume 2014:7 Pages 165—170
DOI https://doi.org/10.2147/CCID.S37327
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Stamatis Gregoriou, Eleftheria Kritsotaki, Alexandros Katoulis, Dimitris Rigopoulos
Second Department of Dermatology and Venereology, Attikon Hospital, University of Athens Medical School, Athens, Greece
Abstract: Acne vulgaris is a common inflammatory chronic disease of the pilosebaceous unit. It often requires long-term treatment, resulting in increased demand for topical medications that are popular with patients in order to achieve long-term compliance. Tazarotene foam 0.1% is a novel formulation of tazarotene. We review efficacy and tolerability studies of the new formulation, and suggest a possible place for the product in the management of acne vulgaris.
Keywords: retinoids, efficacy, safety, tolerability
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.